This past year, the healthcare industry continued to deliver solutions to address COVID-19 and other serious illnesses facing the world, highlighting the valuable contributions our industry is capable of making to society. As we continue to navigate the ongoing pandemic, we had the opportunity to highlight how our company met these challenges in 2021 to advance patient care and outline our vision for our company’s continued evolution and growth at the virtual 40th Annual J.P. Morgan Healthcare Conference that took place earlier this month.
At this year’s conference, we shared our plans for a bright future. Jazz demonstrated strong execution throughout 2020 and 2021 as we progressed our transformation to an innovative global biopharmaceutical leader thanks to a culture of bold innovation, collaboration and inclusion that values integrity, passion and a relentless pursuit of excellence. Most notably, we achieved our goal of delivering five key medicines in two years; and we expanded our organization with the acquisition and integration of GW Pharmaceuticals, enhancing our portfolio and research talent and adding the GW cannabinoid platform, while increasing and diversifying our revenue.
We also announced Vision 2025 to deliver sustainable growth and enhanced value and drive transformation to an innovative, high-growth, biopharmaceutical leader. Through Vision 2025 and our patient-centric approach, Jazz will continue to bring meaningful treatment options to patients in critical need, be a great place to work for employees and generate significant value to shareholders.
From a commercial perspective, we expect to meet our previously announced guidance of more than $3 billion in revenue in 2021, and we are positioned to generate $5 billion in revenue in 2025. Thanks to the hard work of our teams, Jazz remains on track to deliver revenue diversification, with at least 65% of 2022 net product revenue from newly launched or acquired products. Our pipeline is poised to deliver at least five additional novel products by the end of the decade. And through operational excellence and optimizing our global scale, we plan to realize a 5-percentage point improvement in adjusted operating margin from 2021 to 2025.
We remain committed to taking bold steps to deliver life-changing therapies that create new or better standards of care. Our track record of execution, enhanced in-house research and development expertise and exciting GW cannabinoid platform enable us to navigate complex diseases and redefine what’s possible. As we look forward to the year ahead, our teams at Jazz continue to innovate to transform the lives of patients and their families by redefining what living with their disease means.
